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Assessing the protective role of allergic disease in 
gastrointestinal tract cancers using Mendelian randomization 
analysis
To the Editor,
Immune hypersensitivity featured among allergic individuals has 
been proposed to enhance immune surveillance, thereby inhibiting 
abnormal cell growth and thus reduce cancer risk.1,2 Similarly, the 
prophylaxis theory suggests that allergy symptoms may prevent can-
cer development by removing potential carcinogens.2 This hypothesis 
F I G U R E  1   Associations of genetic predisposition to allergic disease with esophageal, gastric, and colorectal cancer. BBJ, indicates 
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envisages a preventive role specifically for cancers of tissues that 
interface with the external environment, such as gastrointestinal 
tract cancers.2 A reduced risk of gastrointestinal tract cancer among 
individuals with self-reported allergic conditions has been observed 
in several but not all observational studies.3,4 However, whether the 
associations are causal remains unclear as observational studies are 
prone to residual confounding. Therefore, we conducted a Mendelian 
randomization study5 to determine the causal role of genetic liability 
to allergic disease in esophageal, gastric, and colorectal cancers.
One hundred and thirty-six single-nucleotide polymorphisms 
(SNPs) associated with at least one allergic disease (asthma, aller-
gic rhinitis, or eczema) at P < 3×10−8 in 180 129 cases and 180 709 
non-cases of European ancestry were considered as instrumental 
variables.6 The 136 SNPs were independent and not in linkage dis-
equilibrium defined by distance >1 Mb and r2 < 0.02. The SNPs ex-
plained around 2.6% of phenotypic variance. Summary-level data for 
the associations of those SNPs with esophageal, gastric, and colorec-
tal cancers were obtained from the UK Biobank, BioBank Japan, and 
FinnGen consortium. The main analysis was based on the multipli-
cative random-effects inverse-variance weighted method, and esti-
mates from the different studies were combined using fixed effects 
meta-analysis. The inverse-variance weighted method under a fixed 
effects model and the weighted median, MR-Egger regression, and 
MR-PRESSO methods were employed as sensitivity analyses. The I2 
(%) statistic and Cochrane's Q value were calculated to assess het-
erogeneity among estimates of individual SNPs. We considered 
TA B L E  1   Associations of genetic predisposition to allergic disease with esophageal, gastric, and colorectal cancer in sensitivity analyses
Esophageal cancer Gastric cancer Colorectal cancer




0.89 0.73, 1.08 .242 0.88 0.72, 1.09 .253 0.91 0.84, 0.98 .015
Weighted median 
method
0.92 0.69, 1.23 .571 0.84 0.61, 1.15 .270 0.96 0.84, 1.08 .489
MR-Egger regression 1.01 0.6, 1.68 .976 1.23 0.71, 2.13 .468 0.91 0.73, 1.15 .442
MR-PRESSO methoda  n/a n/a n/a n/a n/a n/a 0.90 0.83, 0.98 .012
Heterogeneityb  I2 = 0%; Cochrane's Q = 114; 
Phet = .877
I2 = 0%; Cochrane's Q = 137; 
Phet = .393
I2 = 21%; Cochrane's Q = 168; 
Phet = .021




0.79 0.66, 0.96 .017 0.88 0.81, 0.96 .004 0.91 0.83, 0.99 .022
Weighted median 
method
0.65 0.49, 0.86 .003 0.94 0.82, 1.07 .332 0.87 0.76, 0.99 .034
MR-Egger regression 0.65 0.37, 1.14 .130 0.83 0.61, 1.13 .237 0.84 0.66, 1.08 .181
MR-PRESSO methoda  n/a n/a n/a 0.93 0.84, 1.02 .138 n/a n/a n/a
Heterogeneityb  I2 = 0%; Cochrane's Q = 92; 
Phet = .833
I2 = 31%; Cochrane's Q = 154; 
Phet = .002
I2 = 3%; Cochrane's Q = 109; 
Phet = .407




0.93 0.52, 1.67 .803 1.11 0.79, 1.56 .537 0.93 0.79, 1.09 .352
Weighted median 
method
0.79 0.34, 1.85 .586 1.21 0.72, 2.02 .477 1.11 0.88, 1.4 .38
MR-Egger regression 0.30 0.06, 1.43 .129 1.00 0.37, 2.67 .999 0.88 0.55, 1.39 .578
MR-PRESSO methoda  n/a n/a n/a n/a n/a n/a n/a n/a n/a
Heterogeneityb  I2 = 0%; Cochrane's Q = 81; 
Phet = .998
I2 14%; Cochrane's Q 140; Phet = .103 I
2 16%; Cochrane's Q 143; Phet = .078
Pleiotropyc  Intercept = 0.061; Ppleiotropy = .127 Intercept 0.006; Ppleiotropy = .818 Intercept 0.003; Ppleiotropy = .797
aThere was no corrected estimate (n/a) if no outlier was identified. One outlier was identified and removed in the analysis of colorectal cancer based 
on UK Biobank (P value for the distortion test was.815) and two outliers were identified and removed in the analysis of gastric cancer based on 
Biobank Japan (P value for the distortion test was.137). 
bWe observed significant heterogeneity among used SNPs in the analysis of colorectal cancer based on UK Biobank and gastric cancer based on 
Biobank Japan (Phet < .05). 
cPleiotropy was measured by the intercept from MR-Egger regression. Pleiotropy was not detected in any analysis (all P > .05). 
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associations with P values below .017 (where P = .05/3) to represent 
strong evidence of causal associations and associations with P values 
below .05 but above .017 as suggestive evidence of associations.
Genetic liability to allergic disease was associated with lower 
risk of the gastrointestinal tract cancers in the meta-analysis of UK 
Biobank, BioBank Japan, and FinnGen, though the association with 
gastric cancer was not statistically significant after correcting for 
multiple testing (Figure 1). The combined odds ratio was 0.85 (95% 
confidence interval, 0.75, 0.97; P = .016) for esophageal cancer, 0.90 
(95% confidence interval, 0.82, 0.98; P = .020) for gastric cancer, and 
0.91 (95% confidence interval, 0.86, 0.96; P = .001) for colorectal 
cancer for one unit increase in log-transformed odds of allergic dis-
ease. The associations were consistent across data sources with the 
exception of the estimate for gastric cancer in FinnGen which was 
above one but with a broad confidence interval that overlapped the 
estimates in UK Biobank and BioBank Japan. Results were consisent 
in sensitivity analyses for all three cancer outcomes (Table 1).
A potential limitation arises from the fact that we used an instru-
ment for liability to allergic disease that was developed using genetic 
data from individuals of European ancestry and applied to a Japanese 
population. However, a consistent effect of risk alleles of SNPs for 
allergic disease on asthma in BioBank Japan indicates a high validity 
of used instrumental variables and a negligible population bias. In ad-
dition, a robust pattern of established associations in both Asian and 
European populations suggested that the associations were portable 
across populations of distinct ancestries. A further limitation of this 
work is that we cannot make specific inferences about the impact of 
food allergies on cancer risk.
In summary, this MR study supports a protective effect of al-
lergic disease against esophageal and colorectal cancer and possi-
bly gastric cancer. This finding may be useful for further laboratory 
studies to understand the immunological pathways involved in gas-
trointestinal tract carcinogenesis.
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Chronic exposure to benzo(a)pyrene-coupled nanoparticles 
worsens inflammation in a mite-induced asthma mouse model
To the Editor,
Asthma is a highly prevalent chronic inflammatory disease of the air-
ways characterized by airway hyperresponsiveness (AHR) and mucus 
hyperproduction. In the last decades, asthma has been affecting ap-
proximately 20% of the population worldwide and genetic changes 
alone cannot explain this rapid increase. During the same period, 
increased vehicular traffic and other combustion processes have re-
sulted in a significant increase in ambient particle matter (PM) that 
can bind polycyclic aromatic hydrocarbons (PAHs) on their surface. 
PAHs from diesel exhaust and other sources were shown to play a 
role in the exacerbation of allergic immune responses in humans.1 In 
acute asthma models, co-exposure to the PAH, benzo(a)pyrene (B(a)
P), and ovalbumin enhances the production of allergen-specific IgE, 
systemic Th2 response, and airway inflammation in mice.2
Nanoparticles (≤0.1 µm), that represent only 2.3% of total PM 
mass, contribute to 23-30% of the PAHs alveolar deposition com-
ing from roadside sources. Moreover, their small size allows evad-
ing clearance from the lung, leading to long-term retention.3 This 
suggests that nanoparticles are significant contributors of PAHs 
deposition in the lung and thus, may contribute to acute and chronic 
inflammation. However, few studies have evaluated the impact of 
chronic exposure to this pollutant on allergic asthma. Therefore, we 
established a murine allergic asthma model using the house dust 
mite (HDM) allergen, to explore the impact of chronic exposure to 
nanoparticles coupled to PAHs on airway inflammation (Figure S1A 
for exposure model). In this study, we used carbon black nanoparti-
cles from printers uncoated as reference (NP-Ø) and B(a)P-coated 
(NP-B(a)P) as a model of nano-particulate pollutant.
We analyzed the effects of chronic exposure to NP-B(a)P on dif-
ferent asthma parameters. As expected, exposure to HDM-induced 
allergic asthma including increased AHR (Figure S1B), HDM-specific 
IgE, and IgG1 in sera (Figure S1C) and pulmonary inflammation, char-
acterized by elevated total cell numbers in the broncho-alveolar la-
vage (BAL) composed of eosinophils, neutrophils, lymphocytes, and 
macrophages compared to PBS control mice (Figure 1A). Moreover in 
this model, we did not observe airway remodeling (data not shown). 
Neither NP-Ø nor NP-B(a)P nanoparticles alone induced airway in-
flammation. However, NP-B(a)P but not NP-Ø increased AHR in 
non-sensitized mice, suggesting that B(a)P has a specific effect on AHR 
independently of HDM. In HDM-sensitized mice, HDM-induced AHR 
was abolished by NP-Ø and decreased by NP-B(a)P although this one 
remained increased compared to the PBS control group (Figure S1B). 
Surprisingly, both nanoparticles co-exposed with HDM did not modify 
inflammatory cell recruitment in the BAL (Figure 1A) and did not in-
duce bronchial remodeling (data not shown). However, this result was 
not supported by cellular infiltration of lung tissue as shown by hema-
toxylin and eosin histological stain (Figure S1D) and total lung single 
cell suspension (Figure 1B). Indeed, increased total cell numbers were 
enhanced in the lungs of HDM + NP-B(a)P mice compared to HDM-
sensitized mice (Figure 1B). This cellular infiltration was mainly due to 
a significant increase of eosinophils, Ly6C- monocytes/macrophages, 
and CD4+ T cells in HDM-sensitized mice compared to the PBS group 
(Figure 1B). Interestingly, NP-B(a)P significantly modifies the HDM-
induced cell recruitment. Indeed, Ly6C+ as well as Ly6C- monocytes/
macrophages were significantly elevated in HDM + NP-B(a)P com-
pared to HDM-sensitized mice. Moreover, neutrophils, NKT-like cells 
and CD8+ T cells, not recruited in HDM-sensitized mice, were signifi-
cantly increased in lungs from HDM + NP-B(a)P mice (Figure 1B). NKT-
like cells differ from classical NKT by recognizing antigen presented 
through major histocompatibility complex and not through CD1d, 
